Evidence map›Paper›PMID 34943952›Full record

ArticleCells2021

Tolerance Induced by Antigen-Loaded PLG Nanoparticles Affects the Phenotype and Trafficking of Transgenic CD4

Tobias Neef, Igal Ifergan, Sara Beddow, Pablo Penaloza-MacMaster, Kathryn Haskins, Lonnie D Shea, Joseph R Podojil, Stephen D Miller

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Antigen-specific immunotherapy with a CD4Nature communications · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Biomaterial Strategies for Selective Immune Tolerance: Advances and Gaps.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Tobias NeefDepartment of Microbiology-Immunology, School of Medicine, Northwestern University Feinberg, 303 E. Chicago Avenue, Chicago, IL 60611, USA.
Igal IferganDepartment of Microbiology-Immunology, School of Medicine, Northwestern University Feinberg, 303 E. Chicago Avenue, Chicago, IL 60611, USA.ORCID 0000-0003-2945-2580
Sara BeddowDepartment of Microbiology-Immunology, School of Medicine, Northwestern University Feinberg, 303 E. Chicago Avenue, Chicago, IL 60611, USA.
Pablo Penaloza-MacMasterDepartment of Microbiology-Immunology, School of Medicine, Northwestern University Feinberg, 303 E. Chicago Avenue, Chicago, IL 60611, USA.
Kathryn HaskinsDepartment of Immunology and Microbiology, School of Medicine, University of Colorado, Aurora, CO 80045, USA.
Lonnie D SheaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Joseph R PodojilDepartment of Microbiology-Immunology, School of Medicine, Northwestern University Feinberg, 303 E. Chicago Avenue, Chicago, IL 60611, USA.
Stephen D MillerDepartment of Microbiology-Immunology, School of Medicine, Northwestern University Feinberg, 303 E. Chicago Avenue, Chicago, IL 60611, USA.ORCID 0000-0002-9556-0718
Northwestern University · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Michigan · US

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID P OLSON · 2013 to 2026
$24.3M
NPs disguised as apoptotic debris for immune toleranceR01AI155678 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI STEPHEN D MILLER, Lonnie D Shea · 2020 to 2026
$4.7M
Antigen Loaded Particles for Tolerance InductionR01EB013198 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MILLER, STEPHEN D, SHEA, LONNIE D · 2011 to 2018
$4.1M
Interferon-modulated vaccines against HIVDP2DA051912 · NIDA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PENALOZA, PABLO · 2020 to 2023
$2.7M
Juvenile Diabetes Research Foundation 2-SRA-2018-566-S-BJuvenile Diabetes Research Foundation 3-PDF-2018-582-A-NNIAID NIH HHS R01 AI155678NIDA NIH HHS DP2 DA051912NIDDK NIH HHS P30 DK020572NIH HHS R01 AI15567NIH HHS R01 EB013198
6 · The paper itself

Abstract

We have shown that PLG nanoparticles loaded with peptide antigen can reduce disease in animal models of autoimmunity and in a phase 1/2a clinical trial in celiac patients. Clarifying the mechanisms by which antigen-loaded nanoparticles establish tolerance is key to further adapting them to clinical use. The mechanisms underlying tolerance induction include the expansion of antigen-specific CD4

Indexed as

AnimalsAntigensAntigens, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCeliac DiseaseCell LineageEpitopes, T-LymphocyteGlycoproteinsHumansImmune ToleranceMiceMice, TransgenicNanoparticlesOvalbuminPeptide FragmentsAntigensAntigens, ViralEpitopes, T-Lymphocyteglycoprotein peptide 33-41, Lymphocytic choriomeningitis virusGlycoproteinsOVA 323-339OvalbuminPeptide FragmentsPeptidesPolylactic Acid-Polyglycolic Acid CopolymerViral Proteinscell traffickingchemokine receptorsnanoparticlesregulatory T cellstolerancetype 1 diabetes

Identifiers

PMID34943952
PMCPMC8699785
OpenAlexW4200601554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.